Seppo Meri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1984631/publications.pdf

Version: 2024-02-01

		18482	3	1849
197	12,273	62		101
papers	citations	h-index		g-index
209	209	209		11136
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	C1r Upregulates Production of Matrix Metalloproteinase-13 and Promotes Invasion of Cutaneous Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2022, 142, 1478-1488.e9.	0.7	19
2	Complement Factor D Is a Novel Biomarker and Putative Therapeutic Target in Cutaneous Squamous Cell Carcinoma. Cancers, 2022, 14, 305.	3.7	8
3	Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2022, 57, 705-711.	2.4	1
4	Do multiparous women need to work or exercise extra hard to control gestational diabetes?. Journal of Sport and Health Science, 2022, , .	6.5	0
5	Vascular Occlusion in Kidney Biopsy Is Characteristic of Clinically Manifesting Thrombotic Microangiopathy. Journal of Clinical Medicine, 2022, 11, 3124.	2.4	1
6	The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice. Advances in Therapy, 2022, 39, 3896-3915.	2.9	8
7	Intestinal SALSA/dmbt1 levels are decreased in prematurely born infants. Scandinavian Journal of Immunology, 2021, 93, e12987.	2.7	0
8	Diagnostic Dilemma of Thrombotic Microangiopathy in Pregnancy. Kidney International Reports, 2021, 6, 529-533.	0.8	2
9	Proportion of T follicular helper cells in peripheral blood of rheumatoid arthritis patients: a systematic review and meta-analysis. Expert Review of Clinical Immunology, 2021, 17, 667-680.	3.0	5
10	MO085MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE AMONG MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS PATIENTS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
11	Complement factor I upregulates expression of matrix metalloproteinaseâ€13 and â€2 and promotes invasion of cutaneous squamous carcinoma cells. Experimental Dermatology, 2021, 30, 1631-1641.	2.9	8
12	Streptococcus pneumoniae pneumolysin and neuraminidase A convert high-density lipoproteins into pro-atherogenic particles. IScience, 2021, 24, 102535.	4.1	5
13	Exploration of Pyrazolo[1,5â€ <i>a</i>]pyrimidines as Membraneâ€Bound Pyrophosphatase Inhibitors. ChemMedChem, 2021, 16, 3360-3367.	3.2	3
14	In Memory of Sir Peter J. Lachmann, 1931–2020—Bees, Tickover, Factor I and Complement. Viruses, 2021, 13, 1629.	3.3	0
15	Urinary Excretion of Iohexol as a Permeability Marker in a Mouse Model of Intestinal Inflammation: Time Course, Performance and Welfare Considerations. Animals, 2021, 11, 79.	2.3	4
16	COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets. Thrombosis Research, 2021, 208, 129-137.	1.7	12
17	Common Laboratory Mice Are Susceptible to Infection with the SARS-CoV-2 Beta Variant. Viruses, 2021, 13, 2263.	3.3	21
18	Editorial: Function and Dysfunction of Complement Factor H. Frontiers in Immunology, 2021, 12, 831044.	4.8	6

#	Article	IF	Citations
19	Identifying the inheritable component of human thymic T cell repertoire generation in monozygous twins. European Journal of Immunology, 2020, 50, 748-751.	2.9	7
20	Tonsillar surface swab bacterial culture results differ from those of the tonsillar core in recurrent tonsillitis. Laryngoscope, 2020, 130, E791-E794.	2.0	7
21	The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System. Frontiers in Immunology, 2020, 11, 1582.	4.8	228
22	Complement evasion strategies of <i>Borrelia burgdorferi</i> sensu lato. FEBS Letters, 2020, 594, 2645-2656.	2.8	29
23	Microbial complement evasion and vaccine development. FEBS Letters, 2020, 594, 2475-2479.	2.8	1
24	Function and Dysfunction of Complement Factor H During Formation of Lipid-Rich Deposits. Frontiers in Immunology, 2020, 11, 611830.	4.8	17
25	Complement in malaria: immune evasion strategies and role in protective immunity. FEBS Letters, 2020, 594, 2502-2517.	2.8	10
26	Physiology of gangliosides and the role of antiganglioside antibodies in human diseases. Cellular and Molecular Immunology, 2020, 17, 313-322.	10.5	91
27	Streptococci and the complement system: interplay during infection, inflammation and autoimmunity. FEBS Letters, 2020, 594, 2570-2585.	2.8	15
28	No evidence of autoimmunity to human OX1 or OX2 orexin receptors in Pandemrix-vaccinated narcoleptic children. Journal of Translational Autoimmunity, 2020, 3, 100055.	4.0	4
29	Discovery of Membrane-Bound Pyrophosphatase Inhibitors Derived from an Isoxazole Fragment. ACS Medicinal Chemistry Letters, 2020, 11, 605-610.	2.8	7
30	Gliadin Nanoparticles Induce Immune Tolerance to Gliadin in Mouse Models of Celiac Disease. Gastroenterology, 2020, 158, 1667-1681.e12.	1.3	87
31	Activation of the Complement System in the Lower Genital Tract During Pregnancy and Delivery. Frontiers in Immunology, 2020, 11, 563073.	4.8	4
32	Mast cells and complement system: Ancient interactions between components of innate immunity. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2818-2828.	5.7	43
33	Regulation of the Complement System by Pentraxins. Frontiers in Immunology, 2019, 10, 1750.	4.8	66
34	Role of Pneumococcal NanA Neuraminidase Activity in Peripheral Blood. Frontiers in Cellular and Infection Microbiology, 2019, 9, 218.	3.9	18
35	Minor Effect of Antibiotic Pre-treatment on the Engraftment of Donor Microbiota in Fecal Transplantation in Mice. Frontiers in Microbiology, 2019, 10, 2685.	3.5	41
36	Complement dysregulation in glomerulonephritis. Seminars in Immunology, 2019, 45, 101331.	5.6	37

#	Article	IF	Citations
37	Complement in Human Pre-implantation Embryos: Attack and Defense. Frontiers in Immunology, 2019, 10, 2234.	4.8	11
38	Asymmetry in catalysis by <i>Thermotoga maritima</i> membrane-bound pyrophosphatase demonstrated by a nonphosphorus allosteric inhibitor. Science Advances, 2019, 5, eaav7574.	10.3	16
39	Disturbances in complement recognition and control in human disease – An editorial to a special issue on "Complement Regulation― Seminars in Immunology, 2019, 45, 101345.	5.6	1
40	Regulation of the complement system and immunological tolerance in pregnancy. Seminars in Immunology, 2019, 45, 101337.	5.6	43
41	Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment. Clinical Immunology, 2018, 187, 104-106.	3.2	6
42	Complement Factor H and Apolipoprotein E Participate in Regulation of Inflammation in THP-1 Macrophages. Frontiers in Immunology, 2018, 9, 2701.	4.8	27
43	Spontaneous Remission in Paroxysmal Nocturnal Hemoglobinuriaâ€"Return to Health or Transition Into Malignancy?. Frontiers in Immunology, 2018, 9, 1749.	4.8	15
44	Complement Component C3 and Complement Factor B Promote Growth of Cutaneous Squamous Cell Carcinoma. American Journal of Pathology, 2017, 187, 1186-1197.	3.8	63
45	Protective Low-Frequency Variants for Preeclampsia in the Fms Related Tyrosine Kinase 1 Gene in the Finnish Population. Hypertension, 2017, 70, 365-371.	2.7	37
46	Multi-parametric surface plasmon resonance platform for studying liposome-serum interactions and protein corona formation. Drug Delivery and Translational Research, 2017, 7, 228-240.	5.8	37
47	Upregulation of Early and Downregulation of Terminal Pathway Complement Genes in Subcutaneous Adipose Tissue and Adipocytes in Acquired Obesity. Frontiers in Immunology, 2017, 8, 545.	4.8	39
48	Analysis of Complement C3 Gene Reveals Susceptibility to Severe Preeclampsia. Frontiers in Immunology, 2017, 8, 589.	4.8	50
49	3D mosquito screens to create window double screen traps for mosquito control. Parasites and Vectors, 2017, 10, 400.	2.5	4
50	Genetic Variants Contributing to Circulating Matrix Metalloproteinase 8 Levels and Their Association With Cardiovascular Diseases. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	21
51	Genotypic and phenotypic diversity of Lactobacillus rhamnosus clinical isolates, their comparison with strain GG and their recognition by complement system. PLoS ONE, 2017, 12, e0176739.	2.5	21
52	Alternative Pathway of Complement. , 2016, , 325-331.		1
53	SALSA: A Regulator of the Early Steps of Complement Activation on Mucosal Surfaces. Frontiers in Immunology, 2016, 7, 85.	4.8	34
54	Immune activation enhances epithelial nerve growth in provoked vestibulodynia. American Journal of Obstetrics and Gynecology, 2016, 215, 768.e1-768.e8.	1.3	27

#	Article	IF	Citations
55	Food limitation constrains host immune responses to nematode infections. Biology Letters, 2016, 12, 20160471.	2.3	32
56	Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome. Blood, 2016, 127, 2701-2710.	1.4	66
57	Selfâ€nonself discrimination by the complement system. FEBS Letters, 2016, 590, 2418-2434.	2.8	66
58	Pentraxins in the activation and regulation of innate immunity. Immunological Reviews, 2016, 274, 202-217.	6.0	93
59	Reappraisal of Hydatigera taeniaeformis (Batsch, 1786) (Cestoda: Taeniidae) sensu lato with description of Hydatigera kamiyai n. sp International Journal for Parasitology, 2016, 46, 361-374.	3.1	40
60	The Salivary Scavenger and Agglutinin (SALSA) in Healthy and Complicated Pregnancy. PLoS ONE, 2016, 11, e0147867.	2.5	14
61	Dysregulation of adaptive immune responses in complement C3â€deficient patients. European Journal of Immunology, 2015, 45, 915-921.	2.9	12
62	Complement Factor I Promotes Progression of Cutaneous Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2015, 135, 579-588.	0.7	68
63	Anopheles Midgut Epithelium Evades Human Complement Activity by Capturing Factor H from the Blood Meal. PLoS Neglected Tropical Diseases, 2015, 9, e0003513.	3.0	30
64	The outer membrane protease PgtE of Salmonella enterica interferes with the alternative complement pathway by cleaving factors B and H. Frontiers in Microbiology, 2015, 6, 63.	3.5	37
65	Activation of vestibule-associated lymphoid tissue in localized provoked vulvodynia. American Journal of Obstetrics and Gynecology, 2015, 212, 476.e1-476.e8.	1.3	42
66	Complement System in Dermatological Diseases ââ,¬â€œ Fire Under the Skin. Frontiers in Medicine, 2015, 2, 3.	2.6	31
67	Activation of complement system in kidney after ketoprofen-induced kidney injury in sheep. Acta Veterinaria Scandinavica, 2015, 57, 15.	1.6	10
68	Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus. Journal of Autoimmunity, 2015, 63, 68-75.	6.5	48
69	Genetic Analysis of Membrane Cofactor Protein (CD46) of the Complement System in Women with and without Preeclamptic Pregnancies. PLoS ONE, 2015, 10, e0117840.	2.5	13
70	Complement C4 Deficiency – A Plausible Risk Factor for Non-Tuberculous Mycobacteria (NTM) Infection in Apparently Immunocompetent Patients. PLoS ONE, 2014, 9, e91450.	2.5	9
71	The Salivary Scavenger and Agglutinin in Early Life: Diverse Roles in Amniotic Fluid and in the Infant Intestine. Journal of Immunology, 2014, 193, 5240-5248.	0.8	21
72	Complement Factor H: A Biomarker for Progression of Cutaneous Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2014, 134, 498-506.	0.7	73

#	Article	IF	CITATIONS
73	Complement Activation and Regulation in Preeclamptic Placenta. Frontiers in Immunology, 2014, 5, 312.	4.8	104
74	<i>Yersinia pestis</i> <scp>A</scp> il recruitment of <scp>C</scp> 4bâ€binding protein leads to factor lâ€mediated inactivation of covalently and noncovalently bound <scp>C</scp> 4b. European Journal of Immunology, 2014, 44, 742-751.	2.9	26
75	Acute hantavirus infection induces galectin-3-binding protein. Journal of General Virology, 2014, 95, 2356-2364.	2.9	27
76	Pathophysiology of a severe case of Puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant. Antiviral Research, 2014, 111, 23-25.	4.1	32
77	Testing safety of germinated rye sourdough in a celiac disease model based on the adoptive transfer of prolamin-primed memory T cells into lymphopenic mice. American Journal of Physiology - Renal Physiology, 2014, 306, G526-G534.	3.4	15
78	Factor H-Related Proteins. Methods in Molecular Biology, 2014, 1100, 225-236.	0.9	17
79	Antigenic Differences between ASO3 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk. PLoS ONE, 2014, 9, e114361.	2.5	87
80	Impaired intestinal tolerance in the absence of a functional complement system. Journal of Allergy and Clinical Immunology, 2013, 131, 1167-1175.	2.9	13
81	Intracellular Complement Activation Sustains T Cell Homeostasis and Mediates Effector Differentiation. Immunity, 2013, 39, 1143-1157.	14.3	444
82	Complement activation in diseases presenting with thrombotic microangiopathy. European Journal of Internal Medicine, 2013, 24, 496-502.	2.2	78
83	Functional Recruitment of the Human Complement Inhibitor C4BP to <i>Yersinia pseudotuberculosis</i> Outer Membrane Protein Ail. Journal of Immunology, 2012, 188, 4450-4459.	0.8	35
84	The <i>Yersinia pseudotuberculosis</i> Outer Membrane Protein Ail Recruits the Human Complement Regulatory Protein Factor H. Journal of Immunology, 2012, 189, 3593-3599.	0.8	28
85	Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology, 2012, 217, 1122-1128.	1.9	74
86	Opc Expression, LPS Immunotype Switch and Pilin Conversion Contribute to Serum Resistance of Unencapsulated Meningococci. PLoS ONE, 2012, 7, e45132.	2.5	15
87	Acquisition of Complement Factor H Is Important for Pathogenesis of <i>Streptococcus pyogenes </i> Infections: Evidence from Bacterial In Vitro Survival and Human Genetic Association. Journal of Immunology, 2012, 188, 426-435.	0.8	36
88	Interactions between Bordetella pertussis and the complement inhibitor factor H. Molecular Immunology, 2011, 48, 697-705.	2.2	37
89	Dual interaction of factor H with C3d and glycosaminoglycans in host–nonhost discrimination by complement. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2897-2902.	7.1	215
90	Functional Recruitment of Human Complement Inhibitor C4b-Binding Protein to Outer Membrane Protein Rck of Salmonella. PLoS ONE, 2011, 6, e27546.	2.5	29

#	Article	IF	Citations
91	Complement system becomes activated by the classical pathway in intracranial aneurysm walls. Laboratory Investigation, 2010, 90, 168-179.	3.7	56
92	Serotype-Related Variation in Susceptibility to Complement Deposition and Opsonophagocytosis among Clinical Isolates of <i>Streptococcus pneumoniae</i> . Infection and Immunity, 2010, 78, 5252-5261.	2.2	42
93	The Capsular Serotype of <i>Streptococcus pneumoniae </i> Background for Resistance to Complement. Infection and Immunity, 2010, 78, 5262-5270.	2.2	57
94	Human Complement Factor H Binds to Outer Membrane Protein Rck of <i>Salmonella</i> Journal of Immunology, 2010, 185, 1763-1769.	0.8	54
95	Interaction of Pneumococcal Histidine Triad Proteins with Human Complement. Infection and Immunity, 2010, 78, 2089-2098.	2.2	44
96	Expression and sequence diversity of the complement regulating outer surface protein E in Borrelia afzelii vs. Borrelia garinii in patients with erythema migrans or neuroborreliosis. Microbial Pathogenesis, 2010, 49, 363-368.	2.9	7
97	Binding of the complement inhibitor C4b-binding protein to Lyme disease borreliae. Molecular Immunology, 2010, 47, 1299-1305.	2.2	69
98	Screening of DNA-variants in the properdin gene (CFP) in age-related macular degeneration (AMD). Molecular Immunology, 2010, 47, 1334-1336.	2.2	5
99	Lack of Complement Inhibitors in the Outer Intracranial Artery Aneurysm Wall Associates with Complement Terminal Pathway Activation. American Journal of Pathology, 2010, 177, 3224-3232.	3.8	33
100	Clinical Isolates of <i>Streptococcus pneumoniae</i> Protein in a PspC Allele-Dependent Fashion. Journal of Immunology, 2009, 182, 7865-7877.	0.8	75
101	Streptococcus pneumoniae Capsular Serotype 19F Is More Resistant to C3 Deposition and Less Sensitive to Opsonophagocytosis than Serotype 6B. Infection and Immunity, 2009, 77, 676-684.	2.2	64
102	Mannose-binding lectin as a risk factor for acute coronary syndromes. Annals of Medicine, 2009, 41, 591-598.	3.8	23
103	Complement membrane attack complex formation and infectivity of Trichinella spiralis and T. nativa in rats. Veterinary Parasitology, 2009, 159, 263-267.	1.8	9
104	Outer surface protein E antibody response and its effect on complement factor H binding to OspE in Lyme borreliosis. Microbes and Infection, 2008, 10, 135-142.	1.9	10
105	Binding of complement regulators factor H and C4b binding protein to group A streptococcal strains isolated from tonsillar tissue and blood. Microbes and Infection, 2008, 10, 757-763.	1.9	5
106	Microbial complement inhibitors as vaccines. Vaccine, 2008, 26, I113-I117.	3.8	44
107	Binding of the Long Pentraxin PTX3 to Factor H: Interacting Domains and Function in the Regulation of Complement Activation. Journal of Immunology, 2008, 181, 8433-8440.	0.8	173
108	Factor H Binding as a Complement Evasion Mechanism for an Anaerobic Pathogen, <i>Fusobacterium necrophorum </i> /i>. Journal of Immunology, 2008, 181, 8624-8632.	0.8	37

#	Article	IF	Citations
109	Yersinia enterocolitica Serum Resistance Proteins YadA and Ail Bind the Complement Regulator C4b-Binding Protein. PLoS Pathogens, 2008, 4, e1000140.	4.7	109
110	Characterization of Complement Factor H Binding to <i>Yersinia enterocolitica</i> Serotype O:3. Infection and Immunity, 2008, 76, 4100-4109.	2.2	67
111	Functional Mapping of YadA- and Ail-Mediated Binding of Human Factor H to <i>Yersinia enterocolitica</i> Serotype O:3. Infection and Immunity, 2008, 76, 5016-5027.	2.2	55
112	Multifactor Effects and Evidence of Potential Interaction between Complement Factor H Y402H and LOC387715 A69S in Age-Related Macular Degeneration. PLoS ONE, 2008, 3, e3833.	2.5	64
113	Y402H Polymorphism of Complement Factor H Affects Binding Affinity to C-Reactive Protein. Journal of Immunology, 2007, 178, 3831-3836.	0.8	220
114	Human keratinocytes produce the complement inhibitor factor I: Synthesis is regulated by interferon-Î ³ . Molecular Immunology, 2007, 44, 2943-2949.	2.2	26
115	Complement regulation in human atherosclerotic coronary lesions. Atherosclerosis, 2007, 192, 40-48.	0.8	46
116	The surface protease PgtE of <i>Salmonella enterica</i> affects complement activity by proteolytically cleaving C3b, C4b and C5. FEBS Letters, 2007, 581, 1716-1720.	2.8	64
117	New Approaches to the Treatment of Dense Deposit Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 2447-2456.	6.1	231
118	Effect of chronic ethanol consumption on the expression of complement components and acute-phase proteins in liver. Clinical Immunology, 2007, 124, 213-220.	3.2	38
119	Serum Complement C3/C4 Ratio, a Novel Marker for Recurrent Cardiovascular Events. American Journal of Cardiology, 2007, 99, 890-895.	1.6	47
120	Loss of Selfâ€Control in the Complement System and Innate Autoreactivity. Annals of the New York Academy of Sciences, 2007, 1109, 93-105.	3.8	31
121	Function and regulation of the complement system in cardiovascular diseases. Frontiers in Bioscience - Landmark, 2007, 12, 4696.	3.0	70
122	Expression of Complement Regulatory Protein CD55 on Tumor Cells Has an Adverse Effect on the Outcome of Follicular Lymphoma Patients Treated with Immunochemotherapy. Blood, 2007, 110, 1297-1297.	1.4	0
123	Extended haplotypes in the complement factor H (<i>CFH</i>) and CFHâ€related (<i>CFHR</i>) family of genes protect against ageâ€related macular degeneration: Characterization, ethnic distribution and evolutionary implications. Annals of Medicine, 2006, 38, 592-604.	3.8	217
124	Human keratinocytes produce the complement inhibitor factor H: Synthesis is regulated by interferon-1 ³ . Molecular Immunology, 2006, 43, 317-325.	2.2	37
125	Comparison of surface recognition and C3b binding properties of mouse and human complement factor H. Molecular Immunology, 2006, 43, 972-979.	2.2	31
126	COMPLEMENT ACTIVATION ASSOCIATES WITH SACCULARCEREBRAL ARTERY ANEURYSM WALL DEGENERATION AND RUPTURE. Neurosurgery, 2006, 59, 1069-1077.	1.1	145

#	Article	IF	CITATIONS
127	Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO Journal, 2006, 25, 1784-1794.	7.8	149
128	Tumor Necrosis Factor Alpha Enhances Influenza A Virus-Induced Expression of Antiviral Cytokines by Activating RIG-I Gene Expression. Journal of Virology, 2006, 80, 3515-3522.	3.4	128
129	Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Annals of Medicine, 2006, 38, 592-604.	3.8	106
130	Analysis of variants in the complement factor H, the elongation of very long chain fatty acids-like 4 and the hemicentin 1 genes of age-related macular degeneration in the Finnish population. Molecular Vision, 2006, 12, 796-801.	1.1	50
131	Expression of complement factor H binding immunoevasion proteins inBorrelia gariniiisolated from patients with neuroborreliosis. European Journal of Immunology, 2005, 35, 3043-3053.	2.9	52
132	Binding of the Complement Inhibitor C4bp to Serogroup B <i>Neisseria meningitidis</i> . Journal of Immunology, 2005, 174, 6299-6307.	0.8	93
133	Complement Regulator-Acquiring Surface Protein 1 Imparts Resistance to Human Serum in <i>Borrelia burgdorferi</i> . Journal of Immunology, 2005, 175, 3299-3308.	0.8	124
134	Complement Factor H as a Marker for Detection of Bladder Cancer. Clinical Chemistry, 2005, 51, 856-863.	3.2	60
135	Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease). Journal of the American Society of Nephrology: JASN, 2005, 16, 1392-1403.	6.1	354
136	IFN-α Enhances TLR3-Mediated Antiviral Cytokine Expression in Human Endothelial and Epithelial Cells by Up-Regulating TLR3 Expression. Journal of Immunology, 2005, 174, 4289-4294.	0.8	181
137	Regulation of complement activation at the C3-level by serum resistant leptospires. Microbial Pathogenesis, 2005, 39, 139-147.	2.9	119
138	C-reactive protein binds to the $3\hat{l}^2$ -OH group of cholesterol in LDL particles. Biochemical and Biophysical Research Communications, 2005, 329, 1208-1216.	2.1	45
139	Binding of Complement Factor H to Endothelial Cells Is Mediated by the Carboxy-Terminal Glycosaminoglycan Binding Site. American Journal of Pathology, 2005, 167, 1173-1181.	3.8	108
140	The Group B Streptococcal \hat{I}^2 and Pneumococcal Hic Proteins Are Structurally Related Immune Evasion Molecules That Bind the Complement Inhibitor Factor H in an Analogous Fashion. Journal of Immunology, 2004, 172, 3111-3118.	0.8	74
141	Lysine-Dependent Multipoint Binding of the <i>Borrelia burgdorferi</i> Virulence Factor Outer Surface Protein E to the C Terminus of Factor H. Journal of Immunology, 2004, 172, 6195-6201.	0.8	66
142	Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form. European Journal of Immunology, 2004, 34, 2620-2629.	2.9	81
143	Heterogeneous expression of CD59 on human Purkinje cells. Neuroscience Letters, 2004, 362, 21-25.	2.1	8
144	Interdomain Contact Regions and Angles Between Adjacent Short Consensus Repeat Domains. Journal of Molecular Biology, 2004, 344, 1385-1396.	4.2	41

#	Article	IF	CITATIONS
145	The Use of Gene-Expression Profiling to Predict Outcome of Follicular Lymphoma Patients Treated with Rituximab and Chemotherapy Blood, 2004, 104, 1395-1395.	1.4	0
146	Yin and Yang: complement activation and regulation in Alzheimer's disease. Progress in Neurobiology, 2003, 70, 463-472.	5.7	89
147	Complement resistance mechanisms of streptococci. Molecular Immunology, 2003, 40, 95-107.	2.2	118
148	Association Between Complement Factor H and Proteoglycans in Early Human Coronary Atherosclerotic Lesions. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 630-636.	2.4	71
149	Neisserial Lipooligosaccharide Is a Target for Complement Component C4b. Journal of Biological Chemistry, 2003, 278, 50853-50862.	3.4	82
150	Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. Journal of Clinical Investigation, 2003, 111, 1181-1190.	8.2	315
151	Complement Inhibitor Factor H Binding to Lyme Disease Spirochetes Is Mediated by Inducible Expression of Multiple Plasmid-Encoded Outer Surface Protein E Paralogs. Journal of Immunology, 2002, 169, 3847-3853.	0.8	152
152	Complement C3b/C3d and Cell Surface Polyanions Are Recognized by Overlapping Binding Sites on the Most Carboxyl-Terminal Domain of Complement Factor H. Journal of Immunology, 2002, 169, 6935-6944.	0.8	109
153	Onchocerca volvulusMicrofilariae Avoid Complement Attack by Direct Binding of Factor H. Journal of Infectious Diseases, 2002, 185, 1786-1793.	4.0	52
154	<i>Streptococcus pneumoniae</i> Evades Complement Attack and Opsonophagocytosis by Expressing the <i>pspC</i> Locus-Encoded Hic Protein That Binds to Short Consensus Repeats 8–11 of Factor H. Journal of Immunology, 2002, 168, 1886-1894.	0.8	195
155	Activation of Complement Components and Reduced Regulator Expression in Alcohol-Induced Liver Injury in the Rat. Clinical Immunology, 2002, 105, 57-63.	3.2	41
156	Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. American Journal of Cardiology, 2002, 90, 404-408.	1.6	64
157	Herpes simplex virus 1 infected neuronal and skin cells differ in their susceptibility to complement attack. Immunology, 2002, 106, 404-411.	4.4	18
158	Survival of Helicobacter pylori from complement lysis by binding of GPI-anchored protectin (CD59). Gastroenterology, 2001, 120, 470-479.	1.3	37
159	Complement-Regulator Factor H and Related Proteins in Otitis Media with Effusion. Clinical Immunology, 2001, 100, 118-126.	3.2	43
160	Complement C3b interactions studied with surface plasmon resonance technique. International Immunopharmacology, 2001, 1, 495-506.	3.8	49
161	Proteomics: posttranslational modifications, immune responses and current analytical tools. New Biotechnology, 2001, 18, 213-220.	2.7	41
162	Nerve growth factor and brain-derived neurotrophic factor mRNAs are regulated in distinct cell populations of rat heart after ischaemia and reperfusion. Journal of Pathology, 2001, 194, 247-253.	4.5	89

#	Article	IF	Citations
163	Complement C4 Deficiency and HLA Homozygosity in Patients with Frequent Intraoral Herpes Simplex Virus Type 1 Infections. Clinical Infectious Diseases, 2001, 33, 1604-1607.	5.8	32
164	Complement Evasion by Borrelia burgdorferi: Serum-Resistant Strains Promote C3b Inactivation. Infection and Immunity, 2001, 69, 3685-3691.	2.2	167
165	The Complement Regulator Factor H Binds to the Surface Protein OspE of Borrelia burgdorferi. Journal of Biological Chemistry, 2001, 276, 8427-8435.	3.4	332
166	Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell Lymphoma. Leukemia and Lymphoma, 2001, 42, 731-738.	1.3	93
167	Each of the Three Binding Sites on Complement Factor H Interacts with a Distinct Site on C3b. Journal of Biological Chemistry, 2000, 275, 27657-27662.	3.4	191
168	Complement C3 Cleavage and Cytokines Interleukin-1?? and Tumor Necrosis Factor-?? in Otitis Media With Effusion. Laryngoscope, 2000, 110, 1745-1749.	2.0	24
169	Deficiency of Complement Defense Protein CD59 May Contribute to Neurodegeneration in Alzheimer's Disease. Journal of Neuroscience, 2000, 20, 7505-7509.	3.6	127
170	Molecular Mechanisms of Target Recognition in an Innate Immune System: Interactions Among Factor H, C3b, and Target in the Alternative Pathway of Human Complement. Journal of Immunology, 2000, 164, 4742-4751.	0.8	114
171	Complement Activation after Oxidative Stress. American Journal of Pathology, 2000, 156, 1549-1556.	3.8	314
172	Diagnosis of Atypical Neurocysticercosis by Polymerase Chain Reaction Analysis: Case Report. Clinical Infectious Diseases, 1999, 28, 1331-1332.	5.8	17
173	Complement-resistance mechanisms of bacteria. Microbes and Infection, 1999, 1, 785-794.	1.9	108
174	Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Trends in Immunology, 1999, 20, 576-582.	7.5	194
175	The factor H protein family. Immunopharmacology, 1999, 42, 53-60.	2.0	180
176	Factor H and disease: a complement regulator affects vital body functions. Molecular Immunology, 1999, 36, 241-248.	2.2	94
177	FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated. Molecular Immunology, 1999, 36, 809-818.	2.2	95
178	Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin. FEBS Letters, 1999, 462, 345-352.	2.8	118
179	Induced expression of neuronal membrane attack complex and cell death by Alzheimer's \hat{l}^2 -amyloid peptide. Brain Research, 1998, 796, 187-197.	2.2	41
180	Up-regulated expression of decay-accelerating factor (CD55) confers increased complement resistance to sprouting neural cells. European Journal of Immunology, 1998, 28, 1189-1196.	2.9	14

#	Article	IF	Citations
181	Complement-Mediated Killing of Microtumors in Vitro. American Journal of Pathology, 1998, 153, 845-855.	3.8	23
182	Disseminated Toxoplasmosis After Liver Transplantation: Case Report and Review. Clinical Infectious Diseases, 1998, 27, 1327-1328.	5.8	31
183	Acquired Resistance of <i>Escherichia coli </i> to Complement Lysis by Binding of Glycophosphoinositol-Anchored Protectin (CD59). Infection and Immunity, 1998, 66, 1928-1933.	2.2	26
184	Complement-regulatory proteins in ovarian malignancies. , 1997, 70, 14-25.		106
185	Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer., 1997, 71, 1049-1055.		53
186	Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b. FEBS Letters, 1996, 393, 297-302.	2.8	83
187	Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis. Biochemical Journal, 1996, 316, 923-935.	3.7	83
188	Complement activation in the central nervous system following blood–brain barrier damage in man. Annals of Neurology, 1996, 40, 587-596.	5.3	125
189	Activation of the terminal complement cascade in renal infarction. Kidney International, 1995, 47, 918-926.	5.2	29
190	Extracellular domain of type I receptor for transforming growth factor- \hat{l}^2 : molecular modelling using protectin (CD59) as a template. FEBS Letters, 1995, 376, 31-36.	2.8	16
191	Membrane proteins that protect against complement lysis. Seminars in Immunopathology, 1994, 15, 369-396.	4.0	234
192	Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. European Journal of Immunology, 1994, 24, 611-615.	2.9	34
193	Regulation of CD59 expression on the human endothelial cell line EA.hy 926. European Journal of Immunology, 1993, 23, 2511-2516.	2.9	38
194	Acute Schistosomiasis Mansoni in Finnish Hunters Visiting Africa: Need for Appropriate Diagnostic Serology. Scandinavian Journal of Infectious Diseases, 1990, 22, 597-600.	1.5	24
195	A mechanism of activation of the alternative complement pathway by the classical pathway: protection of C3b from inactivation by covalent attachment to C4b. European Journal of Immunology, 1990, 20, 2555-2561.	2.9	55
196	Complement Activation during Cardiopulmonary Bypass in Children. Complement (Basel, Switzerland), 1988, 5, 46-54.	0.9	31
197	Human tumor cells synthesize and secrete alpha-2-macroglobulinin vitro. International Journal of Cancer, 1986, 37, 81-88.	5.1	26